Welcome to our dedicated page for Tiziana Life Sciences Ltd. Common Shares news (Ticker: $TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Ltd. Common Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tiziana Life Sciences Ltd. Common Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tiziana Life Sciences Ltd. Common Shares's position in the market.
Rhea-AI Summary
Tiziana Life Sciences reports positive 3-month neuroimaging scores in multiple sclerosis patients receiving intranasal foralumab. The company announced quantitative data showing improvement in White Matter Z-scores in patients with non-active secondary progressive multiple sclerosis. Dr. Tarun Singhal presented data demonstrating a reduction in microglial activation, indicating a positive effect on brain inflammation. A peer-reviewed journal has published the research findings. Tiziana is currently conducting a double-blind, placebo-controlled study to further evaluate intranasal foralumab's impact.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.33%
Tags
-
Rhea-AI Summary
Tiziana Life Sciences announces FDA allowance for additional patients in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program, with positive clinical data showing improvements in patients' conditions without serious side effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
-
Rhea-AI Summary
Tiziana Life Sciences announced additional positive clinical results from its Expanded Access Program for non-active secondary progressive multiple sclerosis patients, with 70% showing improvement in fatigue after six months of follow-up. All patients stabilized or improved on nasal foralumab treatment. The findings highlight the potential of Tiziana's therapy to address the critical unmet need for individuals living with MS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.94%
Tags
Rhea-AI Summary
Tiziana Life Sciences announced study results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA highlighted in Neurology Today®. The study shows that foralumab attenuates microglial activation in non-active secondary progressive multiple sclerosis patients with progression independent of relapse. The positive results suggest potential benefits for patients with this difficult-to-treat form of MS. The study, presented at the Annual Meeting of the American Academy of Neurology, demonstrates the effect of intranasal foralumab on microglial activation in na-SPMS patients using PET imaging. This breakthrough therapy has the potential to address the unmet need for disease-modifying treatments in progressive MS patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.69%
Tags
-
Rhea-AI Summary
Tiziana Life Sciences presents new quantitative PET imaging data on Foralumab at the American Academy of Neurology meeting. The study shows that intranasal Foralumab attenuates microglial activation and stabilizes disease progression in non-active secondary progressive MS patients with PIRA. The presentation includes encouraging imaging data from the Expanded Access Program, demonstrating the effectiveness of Foralumab in treating MS patients. The study highlights the significant impact of Foralumab in addressing the unmet need for effective treatments in progressive MS patients with PIRA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.49%
Tags
-
Rhea-AI Summary
Tiziana Life Sciences (TLSA) announces an upcoming oral presentation on the treatment of PIRA with Nasal Foralumab for Multiple Sclerosis at the AAN Annual Meeting. Presenter is Tarun Singhal from Harvard Medical School. The presentation aims to dampen microglial activation and stabilize clinical progression in Non-Active Secondary Progressive MS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.51%
Tags
Rhea-AI Summary
Tiziana Life Sciences Ltd. presents positive data on intranasal anti-CD3 monoclonal antibody for Alzheimer’s and Parkinson’s disease at AD/PD conference. The data shows reduction in microglia activation and improvement in behavior in rodent models. Nasal anti-CD3 also reduces hemorrhage and edema associated with ARIA. Neuroinflammation modulation may enhance approved treatments for Alzheimer’s Disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.6%
Tags
-
Rhea-AI Summary
Tiziana Life Sciences Ltd. (TLSA) announced positive findings in a study of patients with na-SPMS, showing improvements in fatigue scores and reduction in microglial activation. The Company is developing breakthrough neuro-immunomodulation therapies and has seen promising results in the Expanded Access (EA) patients. The study is being led by prominent figures in the medical field and has potential implications for the ongoing Phase 2 clinical trial of intranasal foralumab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.56%
Tags
-
News
Rhea-AI Summary
Tiziana Life Sciences Ltd. (TLSA) announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at Biotech Showcase, San Francisco, on January 8-10, 2024. The presentation will focus on the phase 2 trial with intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active secondary progressive multiple sclerosis and other neuroinflammatory and neurodegenerative diseases such as Alzheimer’s. Tiziana’s management will also be participating in one-on-one partnering meetings throughout the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
Rhea-AI Summary
Tiziana Life Sciences Ltd. (TLSA) announced the filing of a new patent application for combining GLP-1ra and foralumab to reduce systemic and vascular inflammation associated with Type 2 Diabetes and non T2D obesity. The application describes the potential for foralumab to provide additional risk reduction for major adverse cardiovascular events. The company aims to provide a new therapeutic option for patients receiving GLP-1 receptor antagonists.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
Tiziana Life Sciences Ltd. Common Shares
Nasdaq:TLSA
TLSA Rankings
TLSA Stock Data
68.19M
61.41M
38.04%
0.78%
0.32%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
London
About TLSA
tiziana life sciences plc is a uk biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. the company is focused on its lead compound, milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (cdk) involved in cell division as well as a number of other protein kinases. milciclib is currently in phase ii clinical trials for thymic carcinoma in patients previously treated with chemotherapy. the company is also in clinical development of foralumab. foralumab is the only fully human engineered anti-human cd3 antibody in clinical development. this phase ii compound has potential application in a wide range of autoimmune and inflammatory diseases, such as ulcerative colitis, multiple sclerosis, type-1 diabetes (t1d), inflammatory bowel disease (ibd), psoriasis and rheumatoid arthritis, where modulation of a t-cell response is desirable. tiziana life sciences’ research